KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Current Assets (2016 - 2025)

Teva Pharmaceutical Industries' Current Assets history spans 17 years, with the latest figure at $13.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 11.11% year-over-year to $13.9 billion, compared with a TTM value of $13.9 billion through Dec 2025, up 11.11%, and an annual FY2025 reading of $13.9 billion, up 11.11% over the prior year.
  • Current Assets for Q4 2025 was $13.9 billion at Teva Pharmaceutical Industries, up from $12.7 billion in the prior quarter.
  • The five-year high for Current Assets was $13.9 billion in Q4 2025, with the low at $11.4 billion in Q3 2023.
  • Average Current Assets over 5 years is $12.3 billion, with a median of $12.3 billion recorded in 2024.
  • Year-over-year, Current Assets decreased 7.63% in 2023 and then grew 11.11% in 2025.
  • Tracing TEVA's Current Assets over 5 years: stood at $12.6 billion in 2021, then fell by 4.15% to $12.1 billion in 2022, then increased by 3.6% to $12.5 billion in 2023, then rose by 0.54% to $12.6 billion in 2024, then increased by 11.11% to $13.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Current Assets are $13.9 billion (Q4 2025), $12.7 billion (Q3 2025), and $12.6 billion (Q2 2025).